Key Phenotypes of Heart Failure with Preserved Ejection Fraction

Savarese G. Becher P.M. Lund L.H. et al.

Global burden of heart failure: a comprehensive and updated review of epidemiology.

Cardiovasc Res. https://doi.org/10.1093/cvr/cvac013GBD 2017 Disease and Injury Incidence and Prevalence Collaborators

Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.

Lancet. 392: 1789-1858Dunlay S.M. Roger V.L. Redfield M.M.

Epidemiology of heart failure with preserved ejection fraction.

Nat Rev Cardiol. 14: 591-602

Evaluation and management of heart failure with preserved ejection fraction.

Nat Rev Cardiol. 17: 559-573Mentz R.J. Kelly J.P. Von Lueder T.G. et al.

Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction.

J Am Coll Cardiol. 64: 2281-2293Solomon S.D. McMurray J.J.V. Anand I.S. et al.

Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction.

N Engl J Med. 381: 1609-1620Anker S.D. Butler J. Filippatos G. et al.

Empagliflozin in heart failure with a preserved ejection fraction.

N Engl J Med. 385: 1451-1461Obokata M. Reddy Y.N.V. Borlaug B.A.

Diastolic dysfunction and heart failure with preserved ejection fraction: understanding mechanisms by using noninvasive methods.

JACC Cardiovasc Imaging. 13: 245-257Andersen M.J. Olson T.P. Melenovsky V. et al.

Differential hemodynamic effects of exercise and volume expansion in people with and without heart failure.

Circ Heart Fail. 8: 41-48Reddy Y.N.V. Obokata M. Verbrugge F.H. et al.

Atrial dysfunction in patients with heart failure with preserved ejection fraction and atrial fibrillation.

J Am Coll Cardiol. 76: 1051-1064Obokata M. Olson T.P. Reddy Y.N.V. et al.

Haemodynamics, dyspnoea, and pulmonary reserve in heart failure with preserved ejection fraction.

Eur Heart J. 39: 2810-2821Gorter T. Obokata M. Reddy Y. et al.

Exercise unmasks distinct pathophysiologic features of pulmonary vascular disease in heart failure with preserved ejection fraction.

Eur Heart J. 39: 2825-2835Kagami K. Takemura M. Yoshida K. et al.

Pulmonary Vascular alterations on ct imaging and outcomes in heart failure with preserved ejection fraction : a preliminary data.

J Card Fail. 27: 1031-1033Obokata M. Reddy Y.N.V. Melenovsky V. et al.

Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction.

Eur Heart J. 40: 689-698Haykowsky M.J. Brubaker P.H. John J.M. et al.

Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction.

J Am Coll Cardiol. 58: 265-274Obokata M. Reddy Y.N.V. Pislaru S.V. et al.

Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction.

Circulation. 136: 6-19Obokata M. Reddy Y.N.V. Melenovsky V. et al.

Myocardial injury and cardiac reserve in patients with heart failure and preserved ejection fraction.

J Am Coll Cardiol. 72: 29-40Hwang S.J. Melenovsky V. Borlaug B.A.

Implications of coronary artery disease in heart failure with preserved ejection fraction.

J Am Coll Cardiol. 63: 2817-2827Cunningham J.W. Claggett B.L. O’Meara E. et al.

Effect of sacubitril/valsartan on biomarkers of extracellular matrix regulation in patients with HFpEF.

J Am Coll Cardiol. 76: 503-514Obokata M. Kane G.C. Reddy Y.N.V. et al.

The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction.

Eur Heart J. 40: 3707-3717

The role of echocardiography in heart failure with preserved ejection fraction: what do we want from imaging?.

Heart Failure Clin. 15: 241-256Harada T. Kagami K. Kato T. et al.

Echocardiography in the diagnostic evaluation and phenotyping of heart failure with preserved ejection fraction.

J Cardiol. 79: 679-690Tamargo M. Obokata M. Reddy Y.N.V. et al.

Functional mitral regurgitation and left atrial myopathy in heart failure with preserved ejection fraction.

Eur J Heart Fail. 22: 489-498Melenovsky V. Hwang S.J. Redfield M.M. et al.

Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction.

Circ Heart Fail. 8: 295-303Harada T. Obokata M. Omote K. et al.

Independent and incremental prognostic value of semiquantitative measures of tricuspid regurgitation severity in heart failure with preserved ejection fraction.

Eur Heart J Cardiovasc Imaging. https://doi.org/10.1093/ehjci/jeaa264Harada T. Obokata M. Omote K. et al.

Functional tricuspid regurgitation and right atrial remodeling in heart failure with preserved ejection fraction.

Am J Cardiol. 162: 129-135Shah S.J. Borlaug B.A. Chung E.S. et al.

Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial.

Lancet. 399: 1130-1140Shah S.J. Katz D.H. Selvaraj S. et al.

Phenomapping for novel classification of heart failure with preserved ejection fraction.

Circulation. 131: 269-279Segar M.W. Patel K.V. Ayers C. et al.

Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis.

Eur J Heart Fail. 22: 148-158Cohen J.B. Schrauben S.J. Zhao L. et al.

Clinical phenogroups in heart failure with preserved ejection fraction.

JACC Heart Fail. 8: 172-184

Health effects of overweight and obesity in 195 countries over 25 Years.

N Engl J Med. 377: 13-27Ward Z.J. Bleich S.N. Cradock A.L. et al.

Projected U.S. state-level prevalence of adult obesity and severe obesity.

N Engl J Med. 381: 2440-2450Reddy Y.N.V. Rikhi A. Obokata M. et al.

Quality of life in heart failure with preserved ejection fraction: importance of obesity, functionalcapacity, and physical inactivity.

Eur J Heart Fail. 22: 1009-1018https://doi.org/10.1002/ejhf.1788

Obesity-related heart failure with preserved ejection fraction.

Heart Failure Clin. 16: 357-368Sorimachi H. Burkhoff D. Verbrugge F.H. et al.

Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction.

Eur J Heart Fail. 23: 1648-1658Reddy Y.N.V. Obokata M. Testani J.M. et al.

Adverse renal response to decongestion in the obese phenotype of heart failure with preserved ejection fraction: renal response of hospitalized obese HFpEF.

J Card Fail. 26: 101-107Harada T. Sunaga H. Sorimachi H. et al.

Pathophysiological role of fatty acid-binding protein 4 in Asian patients with heart failure and preserved ejection fraction.

ESC Heart Fail. 7: 4256-4266Sorimachi H. Obokata M. Takahashi N. et al.

Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction.

Eur Heart J. 42: 1595-1605Haykowsky M.J. Nicklas B.J. Brubaker P.H. et al.

Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction.

JACC Heart Fail. 6: 640-649Koepp K.E. Obokata M. Reddy Y.N.V. et al.

Hemodynamic and functional impact of epicardial adipose tissue in heart failure with preserved ejection fraction.

JACC Heart Fail. 8: 657-666Churchill T.W. Li S.X. Curreri L. et al.

Evaluation of 2 existing diagnostic scores for heart failure with preserved ejection fraction against a comprehensively phenotyped cohort.

Circulation. 143: 289-291Pugliese N.R. Paneni F. Mazzola M. et al.

Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure.

Eur J Heart Fail. 23: 1858-1871

Abdominal obesity is associated with an increased risk of all-cause mortality in patients with HFpEF.

J Am Coll Cardiol. 70: 2739-2749Fontana L. Eagon J.C. Trujillo M.E. et al.

Visceral fat adipokine secretion is associated with systemic inflammation in obese humans.

Diabetes. 56: 1010-1013Reddy Y.N.V. Lewis G.D. Shah S.J. et al.

Characterization of the obese phenotype of heart failure with preserved ejection fraction: a RELAX trial ancillary study.

Mayo Clin Proc. 94: 1199-1209Shah S.J. Kitzman D.W. Borlaug B.A. et al.

Phenotype-specific treatment of heart failure with preserved ejection fraction.

Circulation. 134: 73-90Chandramouli C. Ting W. Id T. et al.

Association of obesity with heart failure outcomes in 11 Asian regions : a cohort study.

PLos Med. 16: e1002916Chang A.Y. Abdullah S.M. Jain T. et al.

Associations among androgens, estrogens, and natriuretic peptides in young women. observations from the dallas heart study.

J Am Coll Cardiol. 49: 109-116Standeven K.F. Hess K. Carter A.M. et al.

Neprilysin, obesity and the metabolic syndrome.

Int J Obes. 35: 1031-1040Obokata M. Reddy Y.N.V. Melenovsky V. et al.

Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity.

Eur J Heart Fail. 24: 353-361Myhre P.L. Vaduganathan M. Claggett B.L. et al.

Association of natriuretic peptides with cardiovascular prognosis in heart failure with preserved ejection fraction: secondary analysis of the TOPCAT randomized clinical trial.

JAMA Cardiol. 02115: 1-6Kitzman D.W. Brubaker P. Morgan T. et al.

Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial.

JAMA. 315: 36-46Shi Q. Wang Y. Hao Q. et al.

Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.

Lancet. 399: 259-269Nguyen T.D. Shingu Y. Amorim P.A. et al.

GLP-1 improves diastolic function and survival in heart failure with preserved ejection fraction.

J Cardiovasc Transl Res. 11: 259-267Sato T. Aizawa Y. Yuasa S. et al.

The effect of dapagliflozin treatment on epicardial adipose tissue volume.

Cardiovasc Diabetol. 17: 6Sha S. Polidori D. Heise T. et al.

Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.

Diabetes Obes Metab. 16: 1087-1095Croteau D. Qin F. Chambers J.M. et al.

Differential effects of sacubitril/valsartan on diastolic function in mice with obesity-related metabolic heart disease.

JACC Basic Transl Sci. 5: 916-927Aroor A.R. Mummidi S. Lopez-Alvarenga J.C. et al.

Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness.

Cardiovasc Diabetol. 20: 80Douketis J.D. Macie C. Thabane L. et al.

Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice.

Int J Obes (Lond). 29: 1153-1167Mikhalkova D. Holman S.R. Jiang H. et al.

Bariatric Surgery–induced cardiac and lipidomic changes in obesity-related heart failure with preserved ejection fraction.

Obesity. 26: 284-290Moussa O. Ardissino M. Heaton T. et al.

Effect of bariatric surgery on long-term cardiovascular outcomes: a nationwide nested cohort study.

Eur Heart J. 41: 2660-2667Shimada Y.J. Tsugawa Y. Brown D.F.M. et al.

Bariatric surgery and emergency department visits and hospitalizations for heart failure exacerbation: population-based, self-controlled series.

J Am Coll Cardiol. 67: 895-903Rush C.J. Berry C. Oldroyd K.G. et al.

Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction.

JAMA Cardiol. 6: 1130-1143Badar A.A. Perez-Moreno A.C. Hawkins N.M. et al.

Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial.

Circ Heart Fail. 8: 717-724Rusinaru D. Houpe D. Szymanski C. et al.

Coronary artery disease and 10-year outcome after hospital admission for heart failure with preserved and with reduced ejection fraction.

Eur J Heart Fail. 16: 967-976

Diagnosis and management of heart failure with preserved ejection frac-tion: 10 key lessons.

Curr Cardiol Rev. 11: 42-52Yang J.H. Obokata M. Reddy Y.N.V. et al.

Endothelium-dependent and independent coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction.

Eur J Heart Fail. 22: 432-441Taqueti V.R. Solomon S.D. Shah A.M. et al.

Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction.

Eur Heart J. 39: 840-849Ling H.Z. Flint J. Damgaard M. et al.

Calculated plasma volume status and prognosis in chronic heart failure.

Eur J Heart Fail. 17: 35-43Shah S.J. Lam C.S.P. Svedlund S. et al.

Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF.

Eur Heart J. 39: 3439-3450Taqueti V.R. Di Carli M.F.

Coronary microvascular disease pathogenic mechanisms and therapeutic options: JACC state-of-the-art review.

J Am Coll Cardiol. 72: 2625-2641Mohammed S.F. Hussain S. Mirzoyev S.A. et al.

Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction.

Circulation. 131: 550-559Massalha S. Walpot J. Dey D. et al.

Epicardial adipose tissue.

JACC Cardiovasc Imaging. 13: 882-884Lopes R.D. Alexander K.P. Stevens S.R. et al.

Initial invasive versus conservative management of stable ischemic heart disease in patients with a history of heart failure or left ventricular dysfunction.

Circulation. 142: 1725-1735Lam C.S.P. Roger V.L. Rodeheffer R.J. et al.

Pulmonary hypertension in heart failure with preserved ejection fraction. a community-based study.

J Am Coll Cardiol. 53: 1119-1126Tan Y.T. Wenzelburger F. Lee E. et al.

The pathophysiology of heart failure with normal ejection fraction: exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist, and longitudinal motion.

J Am Coll Cardiol. 54: 36-46Chamsi-Pasha M.A. Zhan Y. Debs D. et al.

CMR in the evaluation of diastolic dysfunction and phenotyping of HFpEF: current role and future perspectives.

JACC Cardiovasc Imaging. 13: 283-296Borlaug B.A. Olson T.P. Lam C.S.P. et al.

Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction.

J Am Coll Cardiol. 56: 845-854Dunlay S.M. Roger V.L. Weston S.A. et al.

Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction.

Circ Heart Fail. 5: 720-726Shah A.M. Claggett B. Sweitzer N.K. et al.

Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone.

Circulation. 132: 402-414Kosmala W. Przewlocka-Kosmala M. Rojek A. et al.

Association of abnormal left ventricular functional reserve with outcome in heart failure with preserved ejection fraction.

JACC Cardiovasc Imaging. 11: 1737-1746Solomon S.D. Vaduganathan M. Claggett B L. et al.

Sacubitril/valsartan across the spectrum of ejection fraction in heart failure.

Circulation. 141: 352-361Solomon S.D. Claggett B. Lewis E.F. et al.

Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.

Eur Heart J. 37: 455-462Heidenreich P.A. Bozkurt B. Aguilar D. et al.

2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the american college of cardiology/american heart association joint committee on clinical practice guidelines.

Circulation. 145: e895-e1032Park J.J. Choi H.-M. Hwang I.-C. et al.

Myocardial strain for identification of β-blocker responders in heart failure with preserved ejection fraction.

J Am Soc Echocardiogr. 32: 1462-1469.e8Reddy Y.N.V. Obokata M. Egbe A. et al.

Left atrial strain and compliance in the diagnostic evaluation of heart failure with preserved ejection fraction.

Eur J Heart Fail. 21: 891-900Obokata M. Negishi K. Kurosawa K. et al.

Incremental diagnostic value of la strain with leg lifts in heart failure with preserved ejection fraction.

JACC Cardiovasc Imaging. 6: 749-758Shah S.J. Feldman T. Ricciardi M.J. et al.

One-year safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the reduce elevated left atrial pressure in patients with heart failure (REDUCE LAP-HF I) trial: a ran.

JAMA Cardiol. 3: 968-977Feldman T. Mauri L. Kahwash R. et al.

Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction (REDUCE LAP-HF i [Reduce Elevated Left Atrial Pressure in Patients with Heart Failure]): a phase 2, randomized, sham-controlled trial.

Circulation. 137: 364-375Hanff T.C. Kaye D.M. Hayward C.S. et al.

Assessment of predictors of left atrial volume response to a transcatheter interatrial shunt device (from the REDUCE LAP-HF Trial).

Am J Cardiol. 124: 1912-1917Fukamachi K. Horvath D.J. Karimov J.H. et al.

Left atrial assist device to treat patients with heart failure with preserved ejection fraction: initial in vitro study.

J Thorac Cardiovasc Surg. 162: 120-126Solomon S.D. Zile M. Pieske B. et al.

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

Lancet. 380: 1387-1395Aldaas O.M. Lupercio F. Darden D. et al.

Meta-analysis of the usefulness of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction.

Am J Cardiol. 142: 66-73Rattka M. Kühberger A. Pott A. et al.

Catheter ablation for atrial fibrillation in HFpEF patients-A propensity-score-matched analysis.

J Cardiovasc Electrophysiol. 32: 2357-2367Packer D.L. Piccini J.P. Monahan K.H. et al.

Ablation versus drug therapy for atrial fibrillation in heart failure.

Circulation. 143: 1377-1390Gorter T.M. Hoendermis E.S. van Veldhuisen D.J. et al.

Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis.

Eur J Heart Fail. 18: 1472-1487

Is it time to recognize a new phenotype? Heart failure with preserved ejection fraction with pulmonary vascular disease.

Eur Heart J. 38: 2874-2878Fayyaz A.U. Edwards W.D. Maleszewski J.J. et al.

Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction.

Circulation. 137: 1796-1810Hoeper M.M. Meyer K. Rademacher J. et al.

Diffusion capacity and mortality in patients with pulmonary hypertension due to heart failure with preserved ejection fraction.

JACC Heart Fail. 4: 441-449Olson T.P. Johnson B.D. Borlaug B.A.

Impaired pulmonary diffusion in heart failure with preserved ejection fraction.

JACC Heart Fail. 4: 490-498Gorter T.M. van Veldhuisen D.J. Voors A.A. et al.

Right ventricular-vascular coupling in heart failure with preserved ejection fraction and pre- vs. post-capillary pulmonary hypertension.

Eur Heart J Cardiovasc Imaging. 19: 425-432Adamson P.B. Abraham W.T. Bourge R.C. et al.

Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction.

Circ Heart Fail. 7: 935-944Obokata M. Reddy Y.N.V. Shah S.J. et al.

Effects of interatrial shunt on pulmonary vascular function in heart failure with preserved ejection fraction.

J Am Coll Cardiol. 74: 2539-2550Guazzi M. Vicenzi M. Arena R. et al.

Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.

Circulation. 124: 164-174Redfield M.M. Chen H.H. Borlaug B.A. et al.

Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

JAMA. 309: 1268-1277Hoendermis E.S. Liu L.C.Y. Hummel Y.M. et al.

Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.

Eur Heart J. 36: 2565-2573Borlaug B.A. Koepp K.E. Melenovsky V.

Sodium nitrite improves exercise hemodynamics and ventricular performance in heart failure with preserved ejection fraction.

J Am Coll Cardiol. 66: 1672-1682Redfield M.M. Anstrom K.J. Levine J.A. et al.

Isosorbide mononitrate in heart failure with preserved ejection fraction.

N Engl J Med. 373: 2314-2324Borlaug B.A. Anstrom K.J. Lewis G.D. et al.

Effect of inorganic nitrite vs placebo on exercise capacity among patients with heart failure with preserved ejection fraction the INDIE-HFpEF randomized clinical trial.

JAMA. 320: 1764-1773Armstrong P.W. Lam C.S.P. Anstrom K.J. et al.

Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial.

JAMA. 324: 1512-1521Melenovsky V. Hwang S.J. Lin G. et al.

Right heart dysfunction in heart failure with preserved ejection fraction.

Eur Heart J. 35: 3452-3462Ikoma T. Obokata M. Okada K. et al.

Impact of right atrial remodeling in heart failure with preserved ejection fraction.

J Card Fail. 27: 577-584Nagata R. Harada T. Omote K. et al.

Right atrial pressure represents cumulative cardiac burden in heart failure with preserved ejection fraction.

ESC Heart Fail. 9: 1454-1462Asmarats L. Puri R. Latib A. et al.

Transcatheter tricuspid valve interventions: landscape, challenges, and future directions.

J Am Coll Cardiol. 71: 2935-2956Mesquita T. Zhang R. Cho J.H. et al.

Mechanisms of sinoatrial node dysfunction in heart failure with preserved ejection fraction.

Circulation. 145: 45-60Sarma S. Stoller D. Hendrix J. et al.

Mechanisms of chronotropic incompetence in heart failure with preserved ejection fraction.

Circ Heart Fail. 13: e006331Santos M. West E. Skali H. et al.

Resting heart rate and chronotropic response to exercise: prognostic implications in heart failure across the left ventricular ejection fraction spectrum.

J Card Fail. 24: 753-762Kosmala W. Holland D.J. Rojek A. et al.

Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial.

J Am Coll Cardiol. 62: 1330-1338Solomon S.D.

留言 (0)

沒有登入
gif